IVF PulseFree Second Opinion

Investigations after IVF failure

What tests should I ask for after a failed IVF cycle?

The short answer

Start with where your cycle stopped. Few eggs points to ovarian reserve and the protocol; no fertilisation to semen and lab factors; embryos that stopped growing to egg, sperm and lab conditions; failed transfers to the uterus; losses to the ESHRE pregnancy-loss workup. NK cell tests and ERA are not recommended by ESHRE 1,2.

A failed cycle usually arrives with a list of tests someone suggests next. Some of them are worth doing. Others are sold far more often than the evidence supports, and a few are rated by the UK regulator as possibly lowering your chances 4.

The more useful question is not “what else can we test?” but “where exactly did this cycle stop, and what does that point to?” This page sorts the common tests by stage and marks each one as evidence-backed, case by case, or commonly sold but unproven, using ESHRE's 2023 recommendations on implantation failure and on add-ons, ESHRE's 2022 pregnancy-loss guideline and the HFEA's add-on ratings 1,2,3,4.

Reading your report

AMH / AFC
Anti-Müllerian hormone (a blood test) and antral follicle count (a scan). Both estimate how many eggs the ovaries are likely to give in response to stimulation.
MII (metaphase II) oocyte
A mature egg — the only kind that can be injected in ICSI.
2PN
Two pronuclei, seen on day 1. It means an egg fertilised normally.
Total fertilisation failure
None of the eggs fertilised in that cycle.
RIF
Recurrent implantation failure: good embryos transferred repeatedly without a positive pregnancy test.
RPL
Recurrent pregnancy loss: two or more pregnancy losses.
APA / APS
Antiphospholipid antibodies and antiphospholipid syndrome, an immune condition linked to clotting and pregnancy loss.

What did not cause this

  • "Stress before or during treatment made the cycle fail"

    A 2011 BMJ meta-analysis of 14 prospective studies covering 3,583 women found that anxiety or depression before treatment was not associated with whether a cycle produced a pregnancy 9.

  • "Stress caused the miscarriage"

    ESHRE's 2022 pregnancy-loss guideline says couples should be told there is no evidence that stress is a direct cause of pregnancy loss 3.

  • "One failed transfer means something is wrong with me"

    ESHRE's 2023 recommendations suggest investigating only once the embryos transferred so far carried a combined predicted chance of implantation above 60% 1. Below that, chance is the likelier explanation.

Does one failed cycle mean something needs testing?

Not necessarily. ESHRE's 2023 good practice recommendations define recurrent implantation failure by odds, not by a count of cycles. Further investigation is suggested once the embryos transferred so far carried a cumulative predicted chance of implantation above 60% and none implanted 1.

The old “three failed cycles” rule is not the current definition. ESHRE says an estimate of your cumulative chance should at least take account of your age, the number of embryos transferred and, if they were tested, how many were chromosomally normal 1. Below the threshold, the most useful first step is a review of the cycle record, not a new panel of tests.

Your cycle stopped at stimulation: which tests matter if I got fewer eggs than expected?

When few follicles grow or few eggs are collected, the questions are about ovarian reserve and whether the protocol matched it. ESHRE's 2025 stimulation guideline recommends AMH or antral follicle count to predict how the ovaries will respond, and advises against using age, BMI, basal FSH, inhibin B or basal oestradiol for that purpose 5.

The same guideline says AMH and AFC are not recommended for predicting pregnancy or live birth 5. A low AMH helps explain a low egg count; it is not a measure of your chance of a baby. ESHRE also states that a low response on its own is not a reason to cancel a cycle 5.

  • Evidence-backed: AMH or antral follicle count, if you do not have a recent result 5.
  • Worth doing, no test needed: a review of the stimulation chart with the doctor who ran it — starting dose, any mid-cycle changes and follicle sizes at trigger.
  • Commonly sold, unproven: DHEA “to improve response”. ESHRE 2025 does not recommend it for low responders, and says testosterone and growth hormone are probably not recommended either 5.
  • Commonly sold, unproven: platelet-rich plasma (PRP) injected into the ovaries. ESHRE 2023 does not recommend it 2, and the HFEA rates PRP red 4.

Your cycle stopped at fertilisation: what should be checked if the eggs did not fertilise?

Complete fertilisation failure after ICSI happens in about 1–5% of cycles, according to the ESHRE–ALPHA Vienna consensus, which names a failure of egg activation as the main cause 6. ESHRE's add-ons group notes that the activation problem can come from the sperm or the egg 2.

If conventional IVF was used and nothing fertilised, ask whether ICSI would be used next time. For couples without a male factor, ESHRE does not recommend ICSI routinely 2, so the reason for switching should be discussed.

  • Evidence-backed: a repeat semen analysis, performed to the methods in the WHO 2021 laboratory manual 10.
  • Worth asking: how many eggs were mature and how many were injected or inseminated. For ICSI, fertilisation is counted against mature eggs injected 6.
  • Case by case: artificial oocyte activation. ESHRE 2023 recommends it after complete fertilisation failure (0% fertilised), very low fertilisation (under 30%) or globozoospermia, and not routinely otherwise 2.
  • Commonly sold, unproven: sperm DNA fragmentation testing. ESHRE 2023 does not recommend it for routine use 2; the HFEA says results are unlikely to change treatment and gives it no rating 11.

Your cycle stopped at embryo development: what explains embryos that stopped growing?

Embryos that stop before day 5 can reflect the eggs, the sperm or the culture conditions, and one cycle rarely separates them. The fair comparison is with the lab's own results. The Vienna consensus sets a competency value of at least 40%, and a benchmark of at least 60%, for normally fertilised eggs reaching blastocyst on day 5, measured across a lab's reference group of women under 40 using their own fresh eggs 6.

A cycle below that range is not proof of a lab problem, because one woman's eggs are not the reference group. It is still a fair question to ask the lab what its own blastocyst rate is for patients like you 6.

  • Worth asking for: the embryology report, day by day — the fertilisation check on day 1, cell counts on days 2–3 and the blastocyst grade on day 5 or 6 6.
  • Case by case: PGT-A. ESHRE's implantation-failure group says it can be considered after repeated implantation failure 1; ESHRE's add-ons group does not recommend it for routine use 2; ASRM says its value as a routine test for all IVF patients has not been demonstrated 8. It chooses among embryos you already have; it does not create more.
  • Commonly sold, unproven: time-lapse imaging to improve live birth. ESHRE 2023 does not recommend it for that purpose 2, and the HFEA rates it black, meaning no effect 4.
  • Commonly sold, unproven: mitochondrial DNA testing of embryos. ESHRE does not recommend it 1,2.

Your cycle stopped at transfer: which tests help when good embryos did not implant?

This is where ESHRE's 2023 implantation-failure recommendations apply, once the 60% threshold has been passed 1. They contain few tests that everyone should have, and a long list of tests that are not recommended.

On hysteroscopy for everyone: a 2019 Cochrane review found that when only the two trials at low risk of bias were pooled, screening hysteroscopy before IVF did not increase live birth 7. ESHRE says hysteroscopy can be considered, especially when a scan suggests a problem in the uterine cavity 1.

  • Evidence-backed: re-measuring endometrial thickness, and reviewing the oestrogen regimen if the lining stays thin 1.
  • Evidence-backed: antiphospholipid antibody testing if you have other risk factors for clotting; ESHRE says it can be considered even without them 1.
  • Evidence-backed: a review of lifestyle factors such as smoking, for both partners 1.
  • Case by case: 3D ultrasound if not done before; hysteroscopy if a cavity problem is suspected; tubal imaging if a hydrosalpinx is suspected 1.
  • Case by case: testing for chronic endometritis, thyroid function, progesterone levels and both partners' chromosomes (karyotype) 1.
  • Commonly sold, unproven: blood or uterine NK cell tests, uterine T-cell tests, blood cytokines and HLA-C matching. ESHRE 2023 recommends none of them 1.
  • Commonly sold, unproven: endometrial receptivity tests such as ERA. ESHRE's add-ons group does not recommend the tests currently available 2, and the HFEA rates them red, meaning evidence suggests they may reduce effectiveness 4.
  • Commonly sold, unproven: uterine or vaginal microbiome profiling, sperm DNA fragmentation and sperm FISH tests. ESHRE 2023 does not recommend them for implantation failure 1.

Your cycle stopped after a positive test: what workup follows a chemical pregnancy or miscarriage?

A positive test followed by a loss means implantation began. ESHRE's 2022 guideline says a diagnosis of recurrent pregnancy loss could be considered after two or more losses, and sets out which tests are and are not useful 3.

Note one difference between the two ESHRE documents. For implantation failure, sperm DNA fragmentation testing is not recommended 1; for recurrent pregnancy loss, ESHRE says it could be considered for diagnostic purposes 3.

  • Evidence-backed: antiphospholipid antibodies (lupus anticoagulant and anticardiolipin antibodies) after two losses; β2-glycoprotein I antibodies can be considered 3.
  • Evidence-backed: thyroid testing — TSH and TPO antibodies 3.
  • Evidence-backed: an assessment of the uterus, with 3D ultrasound as the preferred method 3.
  • Case by case: genetic testing of pregnancy tissue for explanation, parental karyotypes after individual risk assessment, and sperm DNA fragmentation 3.
  • Not recommended routinely: inherited thrombophilia screening without other risk factors, NK cell testing, prolactin without symptoms, fasting insulin or PCOS screening, and homocysteine 3,13.

What if every test comes back normal?

That is a real result, not a failed investigation. ESHRE's implantation-failure group notes that most treatments offered for repeated failure have been studied without first diagnosing a cause, and asks clinics to limit tests and treatments to those with a clear rationale and data suggesting benefit 1. A normal workup is a reason to question new add-ons, not to add more.

One practical step is worth taking whatever the tests show: ask for your full cycle record, including the embryology notes, while you are still a patient. It is what any second doctor will need.

It depends on…

Where did your cycle stop?

Few follicles grew or few eggs were collected

Ovarian reserve (AMH or AFC) and a protocol review. Skip DHEA and ovarian PRP 2,5.

Eggs were collected but few or none fertilised

Repeat semen analysis, maturity and injection numbers, and whether oocyte activation or ICSI applies 2,6,10.

Eggs fertilised but embryos stopped growing

Day-by-day embryology report and the lab's own blastocyst rate against Vienna benchmarks 6.

Good embryos were transferred but the test was negative

If past ESHRE's 60% threshold 1: lining, cavity and antiphospholipid antibodies where there are risk factors. Not NK cells or ERA 1,2.

Positive test, then a chemical pregnancy or miscarriage

After two losses, ESHRE's workup: antiphospholipid antibodies, thyroid tests and a uterine assessment 3.

How many good-quality embryos have been transferred without implantation?

Not enough to reach a 60% cumulative predicted chance 1

Chance is the likelier explanation. Review the cycle record before adding tests 1.

Enough to pass 60% 1

ESHRE suggests counselling on further investigation and treatment options 1.

Tests by the stage where the cycle stopped

Where it stoppedEvidence-backed or case by caseCommonly sold, unproven
StimulationAMH or AFC; stimulation chart review 5DHEA; ovarian PRP 2,5
FertilisationRepeat semen analysis; oocyte activation in defined cases 2,10Routine sperm DNA fragmentation testing 2
Embryo developmentEmbryology report; lab blastocyst rate; PGT-A case by case 1,6Time-lapse imaging to raise live birth 2,4
TransferLining re-check; APA with risk factors; cavity imaging if in doubt 1NK cells, cytokines, HLA-C, ERA, microbiome 1,2,4
Pregnancy lossAPA, TSH and TPO, uterine assessment after two losses 3Thrombophilia panel without risk factors; NK cells 3

What's worth checking

  • Ask for an estimate of your cumulative chance of implantation so far; ESHRE's threshold for investigation is 60% 1.
  • Low response — AMH or antral follicle count if not recent: evidence-backed 5.
  • Low response — DHEA, growth hormone or ovarian PRP: commonly sold, unproven 2,5.
  • Fertilisation failure — repeat semen analysis to WHO 2021 methods: evidence-backed 10.
  • Fertilisation failure — oocyte activation after 0% or under 30% fertilisation, or globozoospermia: case by case 2.
  • Fertilisation failure — sperm DNA fragmentation test: commonly sold, unproven for routine use 2,11.
  • Embryo arrest — the lab's day-5 blastocyst rate compared with the Vienna benchmarks: worth asking 6.
  • Embryo arrest — time-lapse imaging to improve live birth: commonly sold, unproven 2,4.
  • Failed transfer — endometrial thickness re-check and oestrogen review: evidence-backed 1.
  • Failed transfer — antiphospholipid antibodies if you have clotting risk factors: evidence-backed 1.
  • Failed transfer — hysteroscopy or 3D ultrasound if the cavity is in doubt: case by case 1,7.
  • Failed transfer — NK cell tests, cytokines, HLA-C matching: commonly sold, unproven 1.
  • Failed transfer — ERA or other receptivity tests: commonly sold, unproven 2,4.
  • Two or more losses — antiphospholipid antibodies, TSH and TPO antibodies, uterine assessment: evidence-backed 3.
  • Two or more losses — inherited thrombophilia panel without other risk factors: not recommended routinely 3.

What could change next cycle

9 options, by strength of evidence

  • Mixed, or some groups only 4
  • Not enough studies yet 1
  • Evidence says it doesn't help 4

Ratings follow the evidence reviews cited beside each option, not our opinion.

  • Receptivity-timed transfer (ERA and similar tests)Evidence says it doesn't help

    HFEA rates it red: evidence suggests it may reduce effectiveness; ESHRE 2023 does not recommend current tests 2,4.

  • Immune treatments (intralipid, IVIG, steroids)Evidence says it doesn't help

    ESHRE 2023 does not recommend intralipid or IVIG; the HFEA rates IVIG and steroids red and intralipid grey 2,4.

  • PGT-AMixed, or some groups only

    HFEA: red for live birth for most patients, green for reducing miscarriage; ESHRE says it can be considered after repeated implantation failure 1,4.

  • Endometrial scratchingMixed, or some groups only

    HFEA: unclear (yellow); ESHRE does not recommend it routinely or for implantation failure 1,2,4.

  • Artificial oocyte activationMixed, or some groups only

    Recommended by ESHRE only after 0% or under 30% fertilisation, or globozoospermia; not routinely 2.

  • Hyaluronic acid transfer medium (e.g. EmbryoGlue)Mixed, or some groups only

    ESHRE 2023 recommends it with single embryo transfer; the HFEA rates it unclear (yellow) 2,4.

  • Time-lapse imagingEvidence says it doesn't help

    ESHRE: not recommended to improve live birth; HFEA rates it black, no effect 2,4.

  • Assisted hatchingEvidence says it doesn't help

    ESHRE 2023 found no significant effect on live birth and does not recommend it; the HFEA rates it grey 2,4.

  • Platelet-rich plasma (uterine or ovarian)Not enough studies yet

    ESHRE: not recommended, too few good studies; the HFEA rates PRP red over safety or effectiveness concerns 2,4.

Questions to ask your doctor

  1. Based on my age and the embryos transferred, what was my cumulative predicted chance of implantation, and are we past ESHRE's 60% threshold 1?
  2. At which step did this cycle fall short of what you expected, and what will you change because of it?
  3. For each test you are suggesting, what result would change my next cycle?
  4. Is this test recommended by ESHRE for my situation, or is it an add-on?
  5. What are your lab's fertilisation and blastocyst rates for women my age?
  6. Should my partner have a repeat semen analysis or any other test?

Questions people ask

Does AMH tell me my egg quality?

No. ESHRE's 2025 stimulation guideline recommends AMH or antral follicle count to predict how many eggs stimulation is likely to produce, but not to predict pregnancy or live birth 5. A low AMH explains a smaller egg collection; it does not grade the eggs.

Should my husband also be tested after failed IVF?

Often, yes. A repeat semen analysis is the first step if fertilisation was poor 10. ESHRE's implantation-failure recommendations say both partners' karyotypes can be considered and lifestyle should be reviewed for both 1, and its pregnancy-loss guideline recommends assessing the male partner's lifestyle, including his age 3.

Is a thin endometrium the reason my transfer failed?

It can contribute, but it is rarely the whole answer. ESHRE's 2023 recommendations cite a meta-analysis in which a lining under 7 mm in fresh cycles was linked to lower live birth (odds ratio 0.47), then note that the link weakens after adjusting for other factors and did not predict implantation of chromosomally normal frozen blastocysts in one large study 1.

What does the ERA test actually check, and does it work?

It reads gene activity in an endometrial biopsy and suggests moving the transfer earlier or later. A double-blind randomised trial of 767 patients transferring a single chromosomally normal frozen blastocyst found live birth in 58.5% with receptivity-timed transfer and 61.9% with standard timing (rate ratio 0.95) 12. That trial excluded patients with recurrent implantation failure, so it does not settle the question for them 12. ESHRE reached the same conclusion for routine use 2.

Should I get my NK cells tested?

ESHRE recommends against it, for blood and for uterine tests separately, because better-validated tests of uterine NK cell function and matched treatments do not yet exist 1. The two are different cell populations, and ESHRE's add-ons group notes uterine NK cells have only a weak ability to kill cells and cannot kill placental cells 2. Its pregnancy-loss guideline also advises against NK cell testing after recurrent loss 3.

What is the difference between an HSG, a saline scan and a 3D ultrasound?

They answer different questions. ESHRE's pregnancy-loss guideline says the preferred technique for evaluating the uterus is transvaginal 3D ultrasound, which can distinguish a septate uterus from a bicorporeal one 13. Sonohysterography — saline or gel instilled during a scan — is more accurate than an HSG for uterine malformations and can be used where 3D ultrasound is unavailable, or where tubal patency also has to be investigated 13. After failed transfers, ESHRE suggests 3D ultrasound if it was not done earlier, and tubal imaging if a hydrosalpinx is in doubt 1.

Should I be tested for clotting problems or the MTHFR gene?

For inherited clotting genes, usually not. ESHRE's pregnancy-loss guideline suggests not screening for hereditary thrombophilia outside research, unless you have additional risk factors such as a previous clot or affected family members — and it lists the MTHFR mutation among the hereditary thrombophilias that recommendation covers 13. It also advises against antithrombotic prophylaxis for hereditary thrombophilia with pregnancy loss outside research 13. Antiphospholipid antibodies are a separate matter: ESHRE recommends testing for those after two losses 3.

What TSH level counts as too high before an embryo transfer?

ESHRE's implantation-failure document cites European Thyroid Association guidance that, in the context of assisted reproduction, a TSH above 4 mIU/l may be considered subclinical hypothyroidism needing follow-up and treatment, and below 0.4 mIU/l subclinical hyperthyroidism 1. ESHRE says thyroid assessment can be considered when repeated failure is worked up, but that no specific association with implantation failure has been reported, so it is not generally recommended as an investigation for it 1.

Does low vitamin D affect IVF success?

There is not enough evidence to say so. ESHRE's 2023 implantation-failure document concludes there are insufficient data to recommend routinely measuring vitamin D levels or treating deficiency, and notes that recent data question the accuracy of the measurement itself 1. A randomised placebo-controlled trial in 630 women with low vitamin D starting IVF found clinical pregnancy in 37% with supplementation and 40% with placebo (risk ratio 0.91) 14. ESHRE's pregnancy-loss guideline treats supplementation as general preconception advice, not treatment 3.

Should I be tested for genital TB before my next cycle?

Only through a proper diagnostic pathway. India's INDEX-TB guidelines treat a premenopausal woman presenting with infertility as someone in whom female genital TB should be considered, noting around 11% of patients with it have no symptom other than infertility 15. But they set the diagnosis on one of three findings: a laparoscopic appearance typical of it, a specimen positive for TB bacilli on microscopy or culture, or histopathology consistent with it 15. Anti-TB treatment where infertility is the only presentation should be started only after specialist assessment 15.

What is chronic endometritis, and should I be tested for it?

It is long-standing, often silent inflammation of the uterine lining, identified from plasma cells in an endometrial biopsy. ESHRE says assessment for it can be considered after repeated implantation failure, and antibiotics can be considered if it is found 1. It is candid about the limits: there is no agreed threshold for how many plasma cells count, studies are small or lack controls, and conclusions about the value of diagnosing and treating it are hampered by that lack of standardisation 1.

Should both of us have a karyotype done?

It can be considered, and it is not a routine test. ESHRE's implantation-failure document says karyotyping can be considered to confirm the absence of a chromosomal abnormality in either partner, with genetic counselling and, where relevant, PGT recommended if one is found 1. Its pregnancy-loss guideline says parental karyotyping could be done after individual risk assessment, that there is no need for routine testing, and that cumulative live birth rates are good even when an abnormality is found 3.

Sources

  1. ESHRE Working Group on Recurrent Implantation Failure; Cimadomo D, de los Santos MJ, Griesinger G, Lainas G, Le Clef N, et al. ESHRE good practice recommendations on recurrent implantation failure. Hum Reprod Open. 2023;2023(3):hoad023. ESHRE / Human Reproduction Open
  2. ESHRE Add-ons working group; Lundin K, Bentzen JG, Bozdag G, Ebner T, Harper J, et al. Good practice recommendations on add-ons in reproductive medicine. Hum Reprod. 2023;38(11):2062–2104. ESHRE / Human Reproduction
  3. ESHRE Guideline Group on RPL; Bender Atik R, Christiansen OB, Elson J, Kolte AM, Lewis S, et al. ESHRE guideline: recurrent pregnancy loss: an update in 2022. Hum Reprod Open. 2023;2023(1):hoad002 (with Supplementary Table SI, full list of recommendations). ESHRE / Human Reproduction Open
  4. Human Fertilisation and Embryology Authority. Treatment add-ons with limited evidence (traffic-light ratings; individual add-on pages published 16 October 2023). HFEA (UK regulator)
  5. ESHRE Guideline Group on Ovarian Stimulation; Ata B, Bosch E, Broer S, Griesinger G, Grynberg M, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI: an update in 2025. Hum Reprod. 2026;41(4):498–514. ESHRE / Human Reproduction
  6. ESHRE Special Interest Group of Embryology and Alpha Scientists in Reproductive Medicine. The Vienna consensus: report of an expert meeting on the development of ART laboratory performance indicators. Hum Reprod Open. 2017;2017(2):hox011. ESHRE / ALPHA / Human Reproduction Open
  7. Kamath MS, Bosteels J, D'Hooghe TM, Seshadri S, Weyers S, Mol BWJ, Broekmans FJ, Sunkara SK. Screening hysteroscopy in subfertile women and women undergoing assisted reproduction. Cochrane Database Syst Rev. 2019;4:CD012856. Cochrane
  8. Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. The use of preimplantation genetic testing for aneuploidy: a committee opinion. Fertil Steril. 2024;122(3):421–434. ASRM / SART
  9. Boivin J, Griffiths E, Venetis CA. Emotional distress in infertile women and failure of assisted reproductive technologies: meta-analysis of prospective psychosocial studies. BMJ. 2011;342:d223. BMJ
  10. World Health Organization. WHO laboratory manual for the examination and processing of human semen, 6th edition. Geneva: WHO; 2021. WHO
  11. Human Fertilisation and Embryology Authority. Sperm DNA damage (treatment add-ons information page; published 12 August 2020). HFEA (UK regulator)
  12. Doyle N, Jahandideh S, Hill MJ, Widra EA, Levy M, Devine K. Effect of timing by endometrial receptivity testing vs standard timing of frozen embryo transfer on live birth in patients undergoing in vitro fertilization: a randomized clinical trial. JAMA. 2022;328(21):2117-2125. JAMA
  13. ESHRE Guideline Group on RPL. ESHRE guideline: recurrent pregnancy loss (update 2022) — full guideline version, January 2023. Recommendations 14, 32, 33, 34 and 35, and the hereditary thrombophilia chapter. ESHRE
  14. Somigliana E, Sarais V, Reschini M, Ferrari S, Makieva S, Cermisoni GC, et al. Single oral dose of vitamin D3 supplementation prior to in vitro fertilization and embryo transfer in normal weight women: the SUNDRO randomized controlled trial. Am J Obstet Gynecol. 2021;225(3):283.e1-283.e10. American Journal of Obstetrics and Gynecology
  15. Central TB Division, Ministry of Health and Family Welfare, with WHO Country Office for India and ICMR. INDEX-TB Guidelines: guidelines on extra-pulmonary tuberculosis for India. Section 16.2, Female genital TB. Government of India (Central TB Division) / WHO India / ICMR

Tools for this step

WhatsApp us